BioMarin Delays Resubmission, But Roctavian’s Rocky Road Winding Down

FDA Request Means Company Expects BLA By End Of September

 
• By Alaric DeArment
BioMarin said it would refile Roctavian by the end of September • Source: Shutterstock

More from Gene Therapies

More from Advanced Therapies